An evidence based strategy for follow up after breast conserving treatment for breast cancer

2011 ◽  
Vol 104 (3) ◽  
pp. 223-227 ◽  
Author(s):  
Michael Kontos ◽  
Pratik Roy ◽  
Demetrios Rizos ◽  
Hisham Hamed
Keyword(s):  
Breast Cancer ◽  
Evidence Based ◽  
Breast Conserving Treatment

scholarly journals Detection of local recurrence following breast-conserving treatment in young women with early breast cancer: Optimization of long-term follow-up strategies

The Breast ◽  
2013 ◽  
Vol 22 (3) ◽  
pp. 351-356 ◽  
Author(s):  
Maurice J.C. van der Sangen ◽  
Sanne W.M. Scheepers ◽  
Philip M.P. Poortmans ◽  
Ernest J.T. Luiten ◽  
Grard A.P. Nieuwenhuijzen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Local Recurrence ◽  
Early Breast Cancer ◽  
Young Women ◽  
Breast Conserving Treatment ◽  
Long Term Follow Up

scholarly journals Breast Conservation in Breast Cancer: A Bangladesh Experience

2019 ◽  
Vol 19 (2) ◽  
pp. 55-60
Author(s):  
Parveen shahida Akhtar ◽  
Syeeda Hasina Azam ◽  
Syed Khalid Hasan ◽  
Zafor Mohammad Masud ◽  
Nazrina Khatun ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Local Recurrence ◽  
Hormone Therapy ◽  
Distant Metastasis ◽  
Locally Advanced ◽  
Breast Conserving Surgery ◽  
Breast Conserving Treatment ◽  
Free Survival

Background: Breast cancer is one of the most common cancers in Bangladeshi women. Breast sacrificing treatment is still now the common practice in our country. Now a day’s breast conservative treatment is the standard treatment of breast cancer without compromising the survival. Objective: To observe local recurrence and distant metastasis free survival and overall survival of patients with breast cancer. Methods: Between January 1996 and December 2010, breast conserving treatment was carried out in 237 female patients with breast cancer in different Institutions of Bangladesh. Clinical staging was recorded by physical examination, relevant investigations as well as surgical records. Revised breast conserving surgery was carried out in those who had positive surgical margins or palpable disease. The patients with large but operable cancer or locally advanced cancer were treated by neoadjuvant chemotherapy followed by breast conserving surgery. Systemic adjuvant therapy (chemotherapy and or hormone therapy) and adjuvant radiotherapy were given in all patients. After completion of treatment, the patients were followed up with a standard protocol and data were compiled and analysed. Results: Among 237 patients who underwent breast conserving therapy 13 patients were excluded from the study for various reasons. Total 224 female patients with breast cancer who followed all the treatment schedules and attended for regular follow up were included in the study. They were between 22- 74 years of age, mean age 42.35 years; premenopausal 152 (68%). Sixty five percent (146 patients) was localized cancer (T1-2N0M0), 31.6% was regional cancer (T1-3N1M0), five cases were locally advanced stage (T4bN12M0) and two metastastatic cancer (T2-3N1M1).  All most all (98%) were Infiltrating duct cell carcinoma except four which were Intraductal carcinoma in situ (IDIS).  Estrogen and progesterone receptors were positive in 57% , HER2 positive (+++) in 24% of Patients. Lumpectomy/quandrentectomy with/without axillary clearance was done in 158 patients, revised breast conserving surgery in 53 cases, mastectomy in 8 cases and only biopsy done but no surgical treatment in five cases.Chemotherapy was given in 192 patients (86%); adjuvant 122 cases and neoadjuvant 70 cases. Hormone therapy in 182 patients. Radiotherapy: in 222 cases. Follow up period  was 4 years  to 19 years, median 10 years. Overall survival (OS) and disease free survival (DFS) was 84% and 70% respectively. Local recurrence occurred in 14(6%) cases and distant metastasis in 54 cases (24%). Conclusion: Breast conserving treatment was satisfactory for appropriate case selection and optimized therapy. Survival was no way worse than breast sacrificing treatment. Journal of Surgical Sciences (2015) Vol. 19 (2) : 55-60

scholarly journals Neoadjuvant Concurrent Radiotherapy and Chemotherapy in Early Breast Cancer Patients: Long-Term Results of a Prospective Phase II Trial

Cancers ◽  
2021 ◽  
Vol 13 (20) ◽  
pp. 5107
Author(s):  
Diane Jornet ◽  
Pierre Loap ◽  
Jean-Yves Pierga ◽  
Fatima Laki ◽  
Anne Vincent-Salomon ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Phase Ii ◽  
Combined Treatment ◽  
Breast Conservation ◽  
Long Term Results ◽  
Breast Cancer Patients ◽  
Breast Conserving Treatment ◽  
Long Term Outcome

Background: Neoadjuvant concurrent radiochemotherapy makes it possible to increase the breast conservation rate. This study reports the long term outcome of this treatment. Methods: From 2001 to 2003, 59 women with T2–3 N0–2 M0 invasive breast cancer (BC) not amenable to upfront breast conserving treatment (BCS) were included in this prospective, non-randomized phase II study. Chemotherapy (CT) consisted of four cycles of continuous 5-FU infusion and Vinorelbine. Starting concurrently with the second CT cycle, normofractionated RT was delivered to the breast and LN. Breast surgery was then performed. Results: Median follow-up (FU) was 13 years [3–18]. BCS was performed in 41 (69%) patients and mastectomy in 18 patients, with pathological complete response rate of 27%. Overall and distant-disease free survivals rates at 13 years were 70.9% [95% CI 59.6–84.2] and 71.5% [95% CI 60.5–84.5] respectively. Loco regional and local controls rates were 83.4% [95% CI 73.2–95.0] and 92.1% [95% CI 83.7–100], respectively. Late toxicity (CTCAE-V3) was assessed in 51 patients (86%) with a median follow-up of 13 years. Fifteen presented grade 2 fibrosis (29.4%), 8 (15.7%) had telangiectasia, and 1 had radiodermatitis. Conclusions: This combined treatment provided high long-term local control rates with limited side-effects.

scholarly journals Risk-Reducing Mastectomy and Reconstruction Following Prophylactic Breast Irradiation: Hope Sustained

Cancers ◽  
2021 ◽  
Vol 13 (11) ◽  
pp. 2694
Author(s):  
Merav A. Ben David ◽  
Ella Evron ◽  
Adi F. Rasco ◽  
Ayelet Shai ◽  
Benjamin W. Corn
Keyword(s):  
Breast Cancer ◽  
Risk Reduction ◽  
Contralateral Breast ◽  
Breast Irradiation ◽  
Breast Conserving Treatment ◽  
Mutation Carriers ◽  
Nonrandomized Trial ◽  
Prophylactic Irradiation ◽  
Risk Reducing

Risk-reducing mastectomy (RRM) is often advocated for BRCA1/2 mutation carriers who face a heightened lifetime risk of breast cancer. However, many carrier patients seek alternative risk-reducing measures. In a phase II nonrandomized trial, we previously reported that prophylactic irradiation to the contralateral breast among BRCA carriers undergoing breast-conserving treatment significantly reduced subsequent contralateral breast cancer. Herein, we report the outcome of salvage mastectomy and reconstruction in 11 patients that suffered reoccurrences of breast cancer in either the ipsilateral or contralateral breast or elected to have the procedure for risk reduction during the eight-year follow-up period. Patients’ satisfaction with the procedure and physicians’ assessment of the cosmetic outcome were not inferior for previously irradiated compared to non-irradiated breasts. Although the numbers are small, the results are encouraging and sustain hope in a challenging population. Our findings support continuing research as well as a discussion of risk-reduction alternatives besides mastectomy, including prophylactic breast irradiation, in BRCA1/2 mutation carriers.

scholarly journals Promoting Quality and Evidence-Based Care in Early-Stage Breast Cancer Follow-up

2014 ◽  
Vol 106 (4) ◽  
pp. dju034-dju034 ◽  
Author(s):  
L. N. Henry ◽  
D. F. Hayes ◽  
S. D. Ramsey ◽  
G. N. Hortobagyi ◽  
W. E. Barlow ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Stage ◽  
Early Stage Breast Cancer ◽  
Evidence Based ◽  
Evidence Based Care
Sign in / Sign up

Export Citation Format

Share Document